A Prospective, Randomized, Open-label, Phase I Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Recurrent or Metastatic Prostate Cancer
Condition: Prostate Cancer
Study Type: Interventional
Clinical Trials Identifier NCT 8-digits: NCT07236112
Sponsor: C Ray Therapeutics
Phase: Phase 1
Eligibility:
- Age: minimum 18 Years maximum N/A
- Gender: Male
Inclusion Criteria:
- Participants with recurrence or metastasis of prostate cancer.
- Participants with PSMA-positive lesions.
- Participants must have adequate bone marrow and organ function.
- Participants with an ECOG performance status of 0 or 1.
Exclusion Criteria:
- Any immunotherapy or biological therapy (including antibodies) targeting PSMA within 60 days prior to the day of randomization.
- A superscan is observed in the baseline bone scan.
- Concurrent serious (as determined by the Investigator) medical conditions
- Participants with symptomatic brain metastases, meningeal metastases, or spinal cord compression.
View trial on ClinicalTrials.gov